Expanding U.S. Reach: C2MP Kickoff, JPM Healthcare Conference & SUNY Cannabis Research Highlights
- Canurta
- Jan 30
- 2 min read
Canurta Joins the 11th Annual Canada-Chicago Mentoring Program (C2MP) Kickoff
Canurta is proud to be one of only five Canadian companies selected for the 11th annual Canada-Chicago Mentoring Program (C2MP) kickoff on February 12, 2025. This program, supported by the Trade Commissioner Service and MATTER, accelerates the expansion of Canadian companies into the U.S. market.
During the opening virtual event, Canurta will present its innovations alongside four other high-potential companies. Following this, we will be matched with a cohort of PointB@MATTER mentors, who will provide tailored guidance to refine our U.S. business development strategy.
Through expert mentorship and an expanded network, C2MP will play a vital role in strengthening Canurta’s market positioning in the global life sciences sector.
Canurta Therapeutics Joins Industry Leaders at J.P. Morgan Healthcare Conference
Canurta Therapeutics started the year in San Francisco, where CEO Akeem Gardner participated in the J.P. Morgan Healthcare Conference, the industry’s most influential healthcare investment event. This premier gathering convened global leaders, emerging biotech companies, technology innovators, and key investors to discuss the future of healthcare.
Throughout the event, Canurta engaged in discussions on industry trends, strategic opportunities, and advancements shaping the sector.
Highlighting Neurodegenerative Disease Research at the SUNY Cannabis Conference
On January 14, 2025, CEO Akeem Gardner was a featured speaker at the SUNY Cannabis Conference, presenting "Novel Cannabis Formulations and Their Ability to Mitigate Severe Neurodegenerative Diseases: A Brief History & the Future of Botanical Medicines."
His presentation examined the evolution of cannabis-based therapeutics and their potential role in addressing neurodegenerative diseases. He also shared Canurta’s advancements, milestones, and vision for the future of botanical drug development.
Canurta Hosts IAMALS Tim Lowrey ALS Virtual Panel
On January 23, 2025, Canurta Therapeutics had the privilege of hosting the IAMALS Tim Lowrey ALS Virtual Panel. This session provided a platform for individuals living with ALS to share their experiences, offering valuable perspectives on the challenges and realities of the disease.
At Canurta, the insights of the ALS community inform our mission, reinforcing our commitment to developing meaningful therapeutic solutions.
Click the links below to view the panel as well as the event's brochure from IAMALS.
Canurta's January Milestones
Business Development
Canurta continues to advance through the Creative Destruction Lab's (CDL) strenuous incubator program, successfully making it to the third session, reinforcing the scalability of our technology and the strength of our scientific and business strategy.
Research and Development
Canurta has formally engaged with the FDA on its lead candidate, CNR-401, a novel botanical drug for ALS. We recently submitted our Pre-IND Package, marking a major milestone for the company, with feedback anticipated by the end of February.
Our Research and Development team has completed the method development for the standardization of CNR-401. Additionally, strong positive results were received for the anti-inflammatory and cartilage-preserving properties of the polyphenol-enriched hemp extract in an ex vivo porcine model.
Bioinformatics
Our Bioinformatics team has initiated the groundwork for the future of our informatics AI architecture, conducting in-depth research and strategic planning. Further analysis of our motor neuron disease (MND) model in Zebrafish was conducted with an expanded sample size, increasing statistical power. This deeper analysis has led to the identification of new potential biomarkers and valuable insights, strengthening our understanding of MND and its underlying mechanisms.
